Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21570912.
- Also identified by DOI 10.1016/S1470-2045(11)70056-0 and PMC identifier 3343721.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.
Medical subject headings
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Antineoplastic Agents
- HIV Infections
- Neoplasms